Orient Pharma

Orient Pharma Co., Ltd. (OP) is a specialty pharmaceutical company based in Taiwan and a key subsidiary of the Orient EuroPharma (OEP) Group. Established in 2008, the company focuses on the research, clinical development, and manufacturing of specialty drugs, primarily leveraging its proprietary Multi-Phasic Release Technology (MPRT) platform for modified-release formulations. Its lead product, Methydur, is an innovative treatment for ADHD that has successfully moved through clinical stages to commercialization in several Asian markets. Orient Pharma operates state-of-the-art manufacturing facilities certified by the US FDA, Japan's PMDA, and Taiwan's PIC/S GMP, enabling it to provide high-quality manufacturing and CDMO services to global partners. The company's pipeline continues to expand into therapeutic areas such as central nervous system (CNS) disorders, metabolic diseases, and cardiovascular health.